Caplin Point Laboratories Limited has informed the Exchange regarding a revised press release dated September 20, 2023, titled "Attaching herewith a Press Release regarding grant of final approval by the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, to our Subsidiary Caplin Steriles Limited".